Develops molecular glue degraders that harness the cell's ubiquitin-proteasome system to selectively target and degrade ‘undruggable’ proteins linked to diseases such as cancer, Alzheimer’s, and rare disorders. This approach overcomes limitations of traditional small molecule drugs by eliminating proteins without requiring druggable binding pockets, enabling the development of therapeutics for previously intractable targets.
Funding
Funding not disclosed
Founders
Product
Problem
Many disease-causing proteins lack druggable binding pockets, making them inaccessible to traditional small molecule drugs. This limitation hinders the development of effective treatments for diseases like cancer, Alzheimer’s, and rare disorders.
Solution
Neomorph is developing molecular glue degraders that selectively target and degrade ‘undruggable’ proteins by harnessing the cell's ubiquitin-proteasome system. This approach overcomes the limitations of traditional small molecule drugs, which require druggable binding pockets, by eliminating the target protein entirely, thus removing all of its associated biological activities. Molecular glues work by redirecting E3 ubiquitin ligases to disease-causing proteins, marking them for degradation by the 26S proteasome. This differentiated approach to drug discovery offers the potential to target a broad section of the proteome and tackle diseases previously considered intractable.
Target Audience
The primary target audience includes researchers and pharmaceutical companies focused on developing novel therapeutics for diseases with previously undruggable targets, particularly in oncology, neurodegenerative disorders, and rare diseases.
Features
- Molecular glue degraders that induce proximity between E3 ubiquitin ligases and target proteins
- Targeted protein degradation via the ubiquitin-proteasome system
- Focus on 'undruggable' targets lacking traditional binding pockets
- Novel therapeutics for oncology, Alzheimer’s, and rare disorders
- Platform for discovering and developing innovative new medicines
- Capability to redirect ligase activity to new targets